SCHEMBL20122783

SCHEMBL20122783

COCCn1c2cnccc2c2cc(Cl)cc(-c3ccc(Cl)nc3Cl)c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFATC1 O95644 1/20 0.42
GSK3B P49841 1/20 0.42
DYRK1A Q13627 1/20 0.42
CNR2 P34972 1/20 0.35
CDK4 P11802 4/20 0.35
CDK6 Q00534 3/20 0.35
HASPIN Q8TF76 2/20 0.35
ROCK2 O75116 3/20 0.33
EIF4EBP1 Q13541 2/20 0.32
AAK1 Q2M2I8 1/20 0.32
PDE2A O00408 1/20 0.31
CRHR1 P34998 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
ALOX15 P16050 1/20 0.31
CASP1 P29466 1/20 0.31
HSD17B10 Q99714 1/20 0.31
GRM2 Q14416 1/20 0.31
CCNC P24863 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664345 1.00 NFATC1 (0.42) NFATC1GSK3BDYRK1ACNR2CDK4
SCHEMBL29756290 0.86 ROCK2 (0.38) HASPINROCK2CYP1A2CYP3A4
SCHEMBL20122823 0.86 ROCK2 (0.38) HASPINROCK2CYP1A2CYP3A4
SCHEMBL20122769 0.82 DYRK3 (0.30) GSK3BDYRK1AROCK2
SCHEMBL20122774 0.82 DYRK1A (0.40) GSK3BDYRK1AROCK2
SCHEMBL30664129 0.80 DYRK1A (0.47) NFATC1GSK3BDYRK1AHASPINROCK2
SCHEMBL20122845 0.80 DYRK1A (0.47) NFATC1GSK3BDYRK1AHASPINROCK2
SCHEMBL20122730 0.80 DYRK1A (0.41) NFATC1GSK3BDYRK1ACDK4CDK6
SCHEMBL20122869 0.79 NFATC1 (0.42) NFATC1GSK3BDYRK1ACNR2CDK4
SCHEMBL20122765 0.78 CHUK (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 NFATC1 1647/4885GSK3B 78/4885DYRK1A 493/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 NFATC1 1647/4885GSK3B 78/4885DYRK1A 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.